

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: <sup>KT</sup> Foster et al.

Application No.: 10/518,471

Filing Date: August 15, 2005

For: **REMOVAL OF PRION INFECTIVITY**

Confirmation No.: 7924

Group Art Unit: 1746

Examiner: Bibi S. Carrillo

Date: December 8, 2006

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure is submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

Respectfully submitted,




Alice M. Bonnen  
Registration No.: 57,154

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

Express Mail Label No.: EV 869966948 US

Date of Deposit: December 8, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: **Mail Stop RCE**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Amelia Tauchen

Substitute form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1B**

of

**B**

Application Number

**Complete if Known**

10/518,471

Filing Date

August 15, 2005

First Named Inventor

Foster

Group Art Unit

7924

Examiner Name

Bibi S. Carrillo

Attorney Docket Number

9013-67

**U.S. PATENTS AND PATENT PUBLICATIONS**

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

**OTHER NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	TURK, E. et al. "Purification and properties of the cellular and scrapie hamster prion proteins" <i>Bur. J. Biochem.</i> 176: 21-30 (1988)	
	2.	JAMES, T.L. et al. "Solution structure of the 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform" <i>PNAS</i> 94,:10086-10097 (1997)	
	3.	SAFAR, J et al. "Eight prion strains have PrP <sup>Sc</sup> molecules with different conformations" <i>Nature Medicine</i> 4(10): 1157-1165 (1998)	
	4.	POLYMENIDOU, M. "A short purification process for quantitative isolation of PrP <sup>Sc</sup> from naturally occurring and experimental transmissible spongiform encephalopathies" <i>BMC Infectious Diseases</i> 2(23) (2002)	
	5.	SILVERIA, J.R. et al. "The most infectious prion protein particles" <i>Nature</i> 437: 257-261 (2005) (including supplementary information pp. 1-14)	
	6.	MEYER, R.K. "A monomer-dimer equilibrium of a cellular prion protein (PrP <sup>C</sup> ) not observed with recombinant PrP <sup>Sc</sup> " <i>J. Biol. Chem.</i> 275(48): 28081-38087 (2000)	
	7.	CASTILLA, J. et al. "In vitro generation of infectious scrapie protein" <i>Cell</i> 121: 195-206 (2005)	
	8.	EEC Regulatory Document, Notes for Guidance: Guidelines for Minimizing the Risk of Transmitting Agents Causing Spongiform Encephalopathy via Medicinal Products, <i>Biologicals</i> 20: 155-158 (1992)	
	9.	RIESNER, D. "Biochemistry and Structure of PrP <sup>C</sup> and PrP <sup>Sc</sup> " <i>British Medical Bulletin</i> 66: 21-33 (2003)	
	10.	BENNION, B. "Protein conformation and diagnostic tests: the prion protein" <i>Clinical Chemistry</i> 48(12): 2105-2114 (2002)	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.